The way I see it fwiw is that omega is doing what they have always done. Crossing the ts and dotting the is . The hidden gemme here is the visetect platform inmho
The longer rtc poc test is trialled the better inmv . As the more extensive the trials the more likely hood it will be adopted world wide. That also applies to the moligic tests as well.
Chuggley I was being a little facetious, but am very interested In what is happening on the app front. just not very happy with the leadership at the nhs in terms honoury people involved. love to be proved wrong though
Does anyone know how the directors at the giddy up club are doing together with their scientific advisors with the state of the ..... app is doing. Apparently the nhs is waiting for it .So some geezer at the bookies just told me.
There is usually a lag between the share price and gas prices, but they have jumped over 20 per cent in two days. So we must be in for a jump soon. maybe even this afternoon when the U.S market opens.
It will be interesting to see how long it takes to gain FDA clearance once poc rtc is validated by the u.k. My thought is that Abbot will go for fda registration in the states and then use the consortium to manufacture the product. So my view is the less orders coming from hmg the better as margins will be much higher in the states. They are more likely to buy large amounts and on a large scale inmo. Who knows a u.s firm might then decide to snap up omega
I think the problem at the moment is that some investors are losing faith that the company will deliver. All I can say is that the ceo and board has delivered on everything that they have set out to do so far from the strategic review over three years ago. Allergens has been discontinued, but that is due the large opportunity which has arisen with covid. fwiw I am still holding most of my shares from three years ago as I still believe in them delivering on Food tech/hiv and now covid. I am sure that if we had a couple more institutional holders on board the share price would be more stable though.
I know where you are coming from dodgem I held btg for years. Just imagine what part they could now be playing. However any merger within the consortium together with government holding a percentage could be amazing for uk plc in the long term. Only my thoughts and hopefully not a fantasy
There is a possitive in terms of omega not being mentioned as part of the rtc. It still gives existing and new investors a chance to buy into the shares at a reasonable price. As to a degree we are still under the radar to many potential investors. Inmo
I've posted something similar on advfn. Basically How different in terms of application will the covid test be from visetect cd4 poc test. Visitect is going to be used via a clinicticition. I raised this before covid as I could not understand why it could not be used for home use. So if rtc gets clearance for covid poc test for home use. It should bode well for visitect as this could also end up accessible for home use. In term opening up a market of millions .
Visetect cd4200 is targeting 30 million aids sufferers. The tests will be carried out by health workers. if ten percent of the population becomes infected with covid over time it would currently amount to over seven hundred million people infected. inmv even if the rtc poc test is limited to health care workers administering it the potential market to tap into is huge. That is even without continuous testing.
Newkotb. I think the days of serica staying independent are becoming less and less. If rockrose couldnt stay independent with their aggressive strategy. Then I don't hold out much hope. I'm still amazed that something didn't materialize between the two of them.